Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis

Emmanuel Katsanis, Maria A. Bausero, Augusto C. Ochoa, Cynthia M. Loeffler, Bruce R. Blazar, Arnold S. Leonard, Peter M. Anderson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Pretreatment of A/J mice with CY (25 mg/kg or 75 mg/kg) i.p. on days -10 and -15 followed by IL-2 (50 000 U i.p. on days 0 to +3) resulted in increased lysis of YAC-1 target cells compared to the group receiving IL-2 without previous CY therapy. In contrast, when CY was given on day -5, the cytotoxicity against YAC-1 was not enhanced. Phenotypic analysis of splenocytes obtained from mice treated with CY on day -10 or -15 revealed a relative decrease in L3T4- and Lyt2-positive T cells. In vivo depletion of natural killer (NK) cells by anti-asialoGM1, prior to IL-2 therapy, abrogated the enhancing effect of CY on cytolysis while in vivo elimination of T cells by anti-L3T4 and anti-Lyt2 monoclonal antibodies did not, indicating that in the absence of T cell antigenic challenge, the increased cytolytic function after CY administration is probably mediated through NK cells. These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration.

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalCancer Immunology, Immunotherapy
Volume34
Issue number2
DOIs
StatePublished - Mar 1991
Externally publishedYes

Fingerprint

Cyclophosphamide
Interleukin-2
T-Lymphocytes
Natural Killer Cells
Immunotherapy
Spleen
Monoclonal Antibodies
Therapeutics

Keywords

  • Cyclophosphamide
  • Cytolysis
  • IL-2, NK activity

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Katsanis, E., Bausero, M. A., Ochoa, A. C., Loeffler, C. M., Blazar, B. R., Leonard, A. S., & Anderson, P. M. (1991). Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cancer Immunology, Immunotherapy, 34(2), 74-78. https://doi.org/10.1007/BF01741339

Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. / Katsanis, Emmanuel; Bausero, Maria A.; Ochoa, Augusto C.; Loeffler, Cynthia M.; Blazar, Bruce R.; Leonard, Arnold S.; Anderson, Peter M.

In: Cancer Immunology, Immunotherapy, Vol. 34, No. 2, 03.1991, p. 74-78.

Research output: Contribution to journalArticle

Katsanis, E, Bausero, MA, Ochoa, AC, Loeffler, CM, Blazar, BR, Leonard, AS & Anderson, PM 1991, 'Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis', Cancer Immunology, Immunotherapy, vol. 34, no. 2, pp. 74-78. https://doi.org/10.1007/BF01741339
Katsanis, Emmanuel ; Bausero, Maria A. ; Ochoa, Augusto C. ; Loeffler, Cynthia M. ; Blazar, Bruce R. ; Leonard, Arnold S. ; Anderson, Peter M. / Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. In: Cancer Immunology, Immunotherapy. 1991 ; Vol. 34, No. 2. pp. 74-78.
@article{2bb74624f4b941d9b6f9f52a313ae54f,
title = "Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis",
abstract = "We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Pretreatment of A/J mice with CY (25 mg/kg or 75 mg/kg) i.p. on days -10 and -15 followed by IL-2 (50 000 U i.p. on days 0 to +3) resulted in increased lysis of YAC-1 target cells compared to the group receiving IL-2 without previous CY therapy. In contrast, when CY was given on day -5, the cytotoxicity against YAC-1 was not enhanced. Phenotypic analysis of splenocytes obtained from mice treated with CY on day -10 or -15 revealed a relative decrease in L3T4- and Lyt2-positive T cells. In vivo depletion of natural killer (NK) cells by anti-asialoGM1, prior to IL-2 therapy, abrogated the enhancing effect of CY on cytolysis while in vivo elimination of T cells by anti-L3T4 and anti-Lyt2 monoclonal antibodies did not, indicating that in the absence of T cell antigenic challenge, the increased cytolytic function after CY administration is probably mediated through NK cells. These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration.",
keywords = "Cyclophosphamide, Cytolysis, IL-2, NK activity",
author = "Emmanuel Katsanis and Bausero, {Maria A.} and Ochoa, {Augusto C.} and Loeffler, {Cynthia M.} and Blazar, {Bruce R.} and Leonard, {Arnold S.} and Anderson, {Peter M.}",
year = "1991",
month = "3",
doi = "10.1007/BF01741339",
language = "English (US)",
volume = "34",
pages = "74--78",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis

AU - Katsanis, Emmanuel

AU - Bausero, Maria A.

AU - Ochoa, Augusto C.

AU - Loeffler, Cynthia M.

AU - Blazar, Bruce R.

AU - Leonard, Arnold S.

AU - Anderson, Peter M.

PY - 1991/3

Y1 - 1991/3

N2 - We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Pretreatment of A/J mice with CY (25 mg/kg or 75 mg/kg) i.p. on days -10 and -15 followed by IL-2 (50 000 U i.p. on days 0 to +3) resulted in increased lysis of YAC-1 target cells compared to the group receiving IL-2 without previous CY therapy. In contrast, when CY was given on day -5, the cytotoxicity against YAC-1 was not enhanced. Phenotypic analysis of splenocytes obtained from mice treated with CY on day -10 or -15 revealed a relative decrease in L3T4- and Lyt2-positive T cells. In vivo depletion of natural killer (NK) cells by anti-asialoGM1, prior to IL-2 therapy, abrogated the enhancing effect of CY on cytolysis while in vivo elimination of T cells by anti-L3T4 and anti-Lyt2 monoclonal antibodies did not, indicating that in the absence of T cell antigenic challenge, the increased cytolytic function after CY administration is probably mediated through NK cells. These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration.

AB - We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Pretreatment of A/J mice with CY (25 mg/kg or 75 mg/kg) i.p. on days -10 and -15 followed by IL-2 (50 000 U i.p. on days 0 to +3) resulted in increased lysis of YAC-1 target cells compared to the group receiving IL-2 without previous CY therapy. In contrast, when CY was given on day -5, the cytotoxicity against YAC-1 was not enhanced. Phenotypic analysis of splenocytes obtained from mice treated with CY on day -10 or -15 revealed a relative decrease in L3T4- and Lyt2-positive T cells. In vivo depletion of natural killer (NK) cells by anti-asialoGM1, prior to IL-2 therapy, abrogated the enhancing effect of CY on cytolysis while in vivo elimination of T cells by anti-L3T4 and anti-Lyt2 monoclonal antibodies did not, indicating that in the absence of T cell antigenic challenge, the increased cytolytic function after CY administration is probably mediated through NK cells. These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration.

KW - Cyclophosphamide

KW - Cytolysis

KW - IL-2, NK activity

UR - http://www.scopus.com/inward/record.url?scp=0026046198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026046198&partnerID=8YFLogxK

U2 - 10.1007/BF01741339

DO - 10.1007/BF01741339

M3 - Article

C2 - 1760819

AN - SCOPUS:0026046198

VL - 34

SP - 74

EP - 78

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -